For more than 80 years, men have been told that testosterone fuels prostate cancer. But a more nuanced picture has emerged ...
The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback